Alexander B. Pine, MD, PhD
Assistant Professor of Medicine (Hematology); Assistant Professor of Medicine, Hematology
Research & Publications
Biography
News
Coauthors
Selected Publications
- P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCELRasheed Y, Mirza A, Pine A, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL. HemaSphere 2023, 7: e19857ae. PMCID: PMC10430478, DOI: 10.1097/01.hs9.0000972428.19857.ae.
- P1637: PROTEOMIC PROFILING OF DIFFERENT ANTIPHOSPHOLIPID ANTIBODY-POSITIVE PHENOTYPES: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) REGISTRYButt A, Garcia-Milian R, Goshua G, Gu S, Hwa J, Chun H, Belmont H, Kello N, Branch D, Petri M, Knight J, Willis R, Bertolaccini M, Erkan D, Lee A, Sharda A, Pine A. P1637: PROTEOMIC PROFILING OF DIFFERENT ANTIPHOSPHOLIPID ANTIBODY-POSITIVE PHENOTYPES: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) REGISTRY. HemaSphere 2023, 7: e160607f. PMCID: PMC10429839, DOI: 10.1097/01.hs9.0000973420.16060.7f.
- P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCELMirza A, Pine A, Hamouche R, Rasheed Y, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL. HemaSphere 2023, 7: e1847498. PMCID: PMC10430598, DOI: 10.1097/01.hs9.0000972412.18474.98.
- Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic SyndromeAllen C, Gautam S, Cheng W, Pine A, Podoltsev N, Zeidan A, Lee A, Shallis R. Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome. Acta Haematologica 2023, 146: 287-292. PMID: 37166332, DOI: 10.1159/000530153.
- Comprehensive Characterization of Coagulation Parameters in Venous MalformationsRestrepo V, Pine AB, Butt A, Chang EY, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder HM, Tormey C, Nassiri N, Lee AI, Prozora S.
- CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS).Kewan T, Mirza S, Pine AB, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu SX, Liu L, Vanoudenhove J, Bar B, Neparidze N, Foss FM, Gowda L, Isufi I, Halene S, Lee AI, Seropian S
- Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United StatesStempel JM, Li AJ, Pine AB, Restrepo V, Bewersdorf JP, Stahl M, Podoltsev NA, Mendez L, Shallis RM, Rangachari D, Lee AI, Michaelis LC, Zeidan AM
- Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) RegistryPine AB, Butt B, Garcia-Milian R, Gu SX, Restrepo V, Chock E, Hwa J, Tormey C, Rinder HM, Goshua G, Belmont MH, Bertolaccini M, Branch DW, Erhan D, Kello N, Knight J, Petri M, Willis R, Lee AI, Sharda AV
- Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene VicleucelMirza A, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel. Blood 2022, 140: 10410-10412. DOI: 10.1182/blood-2022-168374.
- Association of iron infusion reactions with ABO blood typeButt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type. European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.
- Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 ThrombosisMadeeva D, Borges K, Shallow M, Juthani P, Wang S, Gupta A, Chun H, Lee A, Pine A. Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 Thrombosis. Blood 2021, 138: 777-777. PMCID: PMC8701622, DOI: 10.1182/blood-2021-153959.
- Challenges in interpreting cytokine data in COVID-19 affect patient care and managementWang SY, Takahashi T, Pine AB, Damsky WE, Simonov M, Zhang Y, Kieras E, Price CC, King BA, Siegel MD, Desir GV, Lee AI, Iwasaki A, Chun HJ. Challenges in interpreting cytokine data in COVID-19 affect patient care and management. PLOS Biology 2021, 19: e3001373. PMID: 34358229, PMCID: PMC8372945, DOI: 10.1371/journal.pbio.3001373.
- Immuno-fibrotic drivers of impaired lung function in post-acute sequelae of SARS-CoV-2Chun HJ, Coutavas E, Pine AB, Lee AI, Yu VL, Shallow MK, Giovacchini CX, Mathews AM, Stephenson B, Que LG, Lee PJ, Kraft BD. Immuno-fibrotic drivers of impaired lung function in post-acute sequelae of SARS-CoV-2. JCI Insight 2021, 6: e148476. PMID: 34111030, PMCID: PMC8410030, DOI: 10.1172/jci.insight.148476.
- Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathyMcConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee A, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal Of Hepatology 2021, 75: 647-658. PMID: 33991637, PMCID: PMC8285256, DOI: 10.1016/j.jhep.2021.04.050.
- Increased complement activation is a distinctive feature of severe SARS-CoV-2 infectionMa L, Sahu S, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish M, Goshua G, Chang C, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo A, Goss C, O’Halloran J, Presti R, Kim A, Gelman A, Dela Cruz C, Lee A, Mudd P, Chun H, Atkinson J, Kulkarni H. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Science Immunology 2021, 6: eabh2259. PMID: 34446527, PMCID: PMC8158979, DOI: 10.1126/sciimmunol.abh2259.
- PRO-THROMBOTIC SIGNATURE FROM NEUTROPHIL ACTIVATION AND DECREASED ADAMTS13 TO VWF RATIO IS A KEY DRIVER OF CARDIAC INJURY IN HOSPITALIZED PATIENTS WITH COVID-19Wang S, Pine A, Mankbadi M, Chang C, Madeeva D, Zhang H, Dajani A, Crandall I, Sugeng L, Lee A, Chun H. PRO-THROMBOTIC SIGNATURE FROM NEUTROPHIL ACTIVATION AND DECREASED ADAMTS13 TO VWF RATIO IS A KEY DRIVER OF CARDIAC INJURY IN HOSPITALIZED PATIENTS WITH COVID-19. Journal Of The American College Of Cardiology 2021, 77: 3193. PMID: 34167644, PMCID: PMC8091195, DOI: 10.1016/s0735-1097(21)04548-4.
- Immuno-fibrotic drivers of impaired lung function in post-acute sequelae of SARS-CoV-2 infection (PASC).Chun HJ, Coutavas E, Pine A, Lee AI, Yu V, Shallow M, Giovacchini CX, Mathews A, Stephenson B, Que LG, Lee PJ, Kraft BD. Immuno-fibrotic drivers of impaired lung function in post-acute sequelae of SARS-CoV-2 infection (PASC). MedRxiv : The Preprint Server For Health Sciences 2021 PMID: 33564789, PMCID: PMC7872384, DOI: 10.1101/2021.01.31.21250870.
- A neutrophil activation signature predicts critical illness and mortality in COVID-19Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang CH, Zhang H, Shallow M, Bahel P, Owusu K, Yamamoto Y, Arora T, Atri DS, Patel A, Gbyli R, Kwan J, Won CH, Dela Cruz C, Price C, Koff J, King BA, Rinder HM, Wilson FP, Hwa J, Halene S, Damsky W, van Dijk D, Lee AI, Chun HJ. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Advances 2021, 5: 1164-1177. PMID: 33635335, PMCID: PMC7908851, DOI: 10.1182/bloodadvances.2020003568.
- Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection.Ma L, Sahu SK, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish M, Goshua G, Chang CH, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo AM, Goss CW, O'Halloran JA, Presti RM, Kim AH, Gelman AE, Cruz CD, Lee AI, Mudd P, Chun HJ, Atkinson JP, Kulkarni HS. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. BioRxiv : The Preprint Server For Biology 2021 PMID: 33655244, PMCID: PMC7924264, DOI: 10.1101/2021.02.22.432177.
- Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysisMeizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, DeFilippo N, Keating C, Liu Y, Mankbadi M, McManus D, Wang SY, Price C, Bona RD, Chaar C, Chun HJ, Pine AB, Rinder HM, Siner JM, Neuberg DS, Owusu KA, Lee AI. Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis. American Journal Of Hematology 2021, 96: 471-479. PMID: 33476420, PMCID: PMC8013588, DOI: 10.1002/ajh.26102.
- A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetranceMendoza H, Chen PH, Pine AB, Siddon AJ, Bale AE, Gowda L, Killie A, Richards J, Varin-Tremblay C, Kloss R, Podoltsev NA. A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance. Leukemia & Lymphoma 2020, 62: 1251-1254. PMID: 33345654, DOI: 10.1080/10428194.2020.1861276.
- VWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional StudyMadeeva D, Christian J, Goshua G, Chun H, Lee A, Pine A. VWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional Study. Blood 2020, 136: 34-35. PMCID: PMC8330245, DOI: 10.1182/blood-2020-142917.
- Circulating markers of angiogenesis and endotheliopathy in COVID‐19Pine AB, Meizlish ML, Goshua G, Chang C, Zhang H, Bishai J, Bahel P, Patel A, Gbyli R, Kwan JM, Won CH, Price C, Dela Cruz CS, Halene S, Dijk D, Hwa J, Lee AI, Chun HJ. Circulating markers of angiogenesis and endotheliopathy in COVID‐19. Pulmonary Circulation 2020, 10: 1-4. PMID: 33282193, PMCID: PMC7691906, DOI: 10.1177/2045894020966547.
- Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional studyGoshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.
- Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based surveyPine AB, Chokr N, Stahl M, Steensma DP, Sekeres MA, Litzow MR, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia & Lymphoma 2020, 61: 1455-1464. PMID: 32026740, DOI: 10.1080/10428194.2020.1723013.
- Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' SurveyPine A, Lee A. Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey. Blood 2019, 134: 2097-2097. DOI: 10.1182/blood-2019-130200.
- Getting personal with myelodysplastic syndromes: is now the right time?Chokr N, Pine AB, Bewersdorf JP, Shallis RM, Stahl M, Zeidan AM. Getting personal with myelodysplastic syndromes: is now the right time? Expert Review Of Hematology 2019, 12: 215-224. PMID: 30977414, PMCID: PMC6540985, DOI: 10.1080/17474086.2019.1592673.
- Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based SurveyPine A, Chokr N, Stahl M, Steensma D, Sekeres M, Litzow M, Luger S, Stone R, Greenberg P, Bejar R, Gore S, Zeidan A. Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey. Blood 2018, 132: 1825-1825. DOI: 10.1182/blood-2018-99-113888.
- Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right placeShallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review Of Hematology 2018, 11: 715-726. PMID: 30024293, DOI: 10.1080/17474086.2018.1503049.
- Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic StudyLy KI, Oakley DH, Pine AB, Frosch MP, Chiou SH, Betensky RA, Pomerantz SR, Hochberg FH, Batchelor TT, Cahill DP, Dietrich J. Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. The Oncologist 2018, 24: 402-413. PMID: 30097523, PMCID: PMC6519760, DOI: 10.1634/theoncologist.2018-0086.
- Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey*Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey*. Leukemia & Lymphoma 2018, 59: 2723-2726. PMID: 29667455, DOI: 10.1080/10428194.2018.1452219.
- Atrial Fibrillation in a Patient With an Accessory PathwaySilverman A, Taneja S, Benchetrit L, Makusha P, McNamara RL, Pine AB. Atrial Fibrillation in a Patient With an Accessory Pathway. Journal Of Investigative Medicine High Impact Case Reports 2018, 6: 2324709618802870. PMID: 30283806, PMCID: PMC6166305, DOI: 10.1177/2324709618802870.
- Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United StatesPine AB, Lee E, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia‐Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 2016, 57: 289-295. PMID: 27878822, PMCID: PMC5309168, DOI: 10.1111/trf.13934.
- North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute LeukemiaPine A, Lee E, Sekeres M, Steensma D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba H, Garcia-Manero G, Lee A, Podoltsev N, Barbarotta L, Hendrickson J, Gore S, Zeidan A. North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood 2015, 126: 1138-1138. DOI: 10.1182/blood.v126.23.1138.1138.
- Clinical, Histopathologic, and Magnetic Resonance Imaging (MRI) Findings in Gliomatosis Cerebri (P03.139)Ly I, Pine A, Stemmer-Rachamimov A, Hochberg F, Dietrich J. Clinical, Histopathologic, and Magnetic Resonance Imaging (MRI) Findings in Gliomatosis Cerebri (P03.139). Neurology 2012, 78: p03.139-p03.139. DOI: 10.1212/wnl.78.1_meetingabstracts.p03.139.
- Use of complementary and alternative medicine by patients with cancer.Watkins C, Fernandez-Robles C, Miller K, Pine A, Stern T. Use of complementary and alternative medicine by patients with cancer. The Primary Care Companion For CNS Disorders 2011, 13 PMID: 21977340, PMCID: PMC3184577, DOI: 10.4088/pcc.10f01011.